Abstract

Aims

Hypertrophic cardiomyopathy (HCM) is a leading cause of sudden cardiac death (SCD) in young adults. Current risk algorithms provide only a crude estimate of risk and fail to account for the different effect size of individual risk factors. The aim of this study was to develop and validate a new SCD risk prediction model that provides individualized risk estimates.

Methods and results

The prognostic model was derived from a retrospective, multi-centre longitudinal cohort study. The model was developed from the entire data set using the Cox proportional hazards model and internally validated using bootstrapping. The cohort consisted of 3675 consecutive patients from six centres. During a follow-up period of 24 313 patient-years (median 5.7 years), 198 patients (5%) died suddenly or had an appropriate implantable cardioverter defibrillator (ICD) shock. Of eight pre-specified predictors, age, maximal left ventricular wall thickness, left atrial diameter, left ventricular outflow tract gradient, family history of SCD, non-sustained ventricular tachycardia, and unexplained syncope were associated with SCD/appropriate ICD shock at the 15% significance level. These predictors were included in the final model to estimate individual probabilities of SCD at 5 years. The calibration slope was 0.91 (95% CI: 0.74, 1.08), C-index was 0.70 (95% CI: 0.68, 0.72), and D-statistic was 1.07 (95% CI: 0.81, 1.32). For every 16 ICDs implanted in patients with ≥4% 5-year SCD risk, potentially 1 patient will be saved from SCD at 5 years. A second model with the data set split into independent development and validation cohorts had very similar estimates of coefficients and performance when externally validated.

Conclusion

This is the first validated SCD risk prediction model for patients with HCM and provides accurate individualized estimates for the probability of SCD using readily collected clinical parameters.

You do not currently have access to this article.

Comments

1 Comment
"Re:""A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD)""O'Mahony, et al., 35 (30): 2010-2020 doi:10.1093/eurheartj/eht439"
18 November 2014
Dana Konecny, Research fellow
Mayo Clinic, Rochester, Minnesota, USA
Dear colleagues,
After reading your captivating manuscript titled “A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy” published in the European Heart Journal, I wanted to inquire about the availability of data on the racial and ethnic background of the patients included in this study. Given that your analysis encompasses over 24 thousand patient-years of follow up of patients with hypertrophic cardiomyopathy, was there perhaps a relatively sufficient number of non-Caucasian patients to allow for the evaluation of “ethnicity” as one of the clinical characteristics in your model which pertains to the end point of sudden cardiac death or its equivalents? Perhaps it would be of interest to other investigators to explore this issue, especially in the context of the status quo in which it has been difficult to establish a clear cut link between a particular genotype and an adverse phenotype in the form of sudden death. I expect that very few medical centers (or even any countries) would care for a sufficient number of patients with hypertrophic cardiomyopathy to allow for the analysis of ethnicity as a risk factor, but perhaps the well powered data set analyzed by your group could shed further light on this issue.
With kind regards,
Dr. Dana Konecny
Submitted on 18/11/2014 7:00 PM GMT